Neogen Corp(NEOG) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -0.26 | Insider Own | 0.99% | Shs Outstand | 218.3M | Perf Week | 4.99% |
| Market Cap | 2.67B | Forward P/E | 27.54 | EPS next Y | 33% | Insider Trans | 0.04% | Shs Float | 216.2M | Perf Month | -11.26% |
| Enterprise Value | 3.27B | PEG | 1.18 | EPS next Q | 0.06 | Inst Own | 109.84% | Short Float | 5.48% | Perf Quarter | 32.86% |
| Income | -0.06B | P/S | 3.02 | EPS this Y | 4.17% | Inst Trans | 2.07% | Short Ratio | 3.56 | Perf Half Y | 29.21% |
| Sales | 0.88B | P/B | 1.28 | EPS next 5Y | 23.31% | ROA | -1.68% | Short Interest | 11.85M | Perf YTD | 74.68% |
| Book/sh | 9.56 | P/C | 15.5 | EPS past 3/5Y | 33.08% - | ROE | -2.67% | 52W High | -14.38% ($14.26) | Perf Year | 97.25% |
| Cash/sh | 0.79 | P/FCF | 53.58 | Sales past 3/5Y | 1.91% 13.19% | ROIC | -1.96% | 52W Low | 127.37% ($5.37) | Perf 3Y | -21.12% |
| Dividend Est. | - | EV/EBITDA | 27.77 | EPS Y/Y TTM | 94.64% | Gross Margin | 37.01% | Volatility(W/M) | 2.86% 5.4% | Perf 5Y | -70.97% |
| Dividend TTM | - | EV/Sales | 3.7 | Sales Y/Y TTM | -0.33% | Oper. Margin | 0.01% | ATR (14) | 0.54 | Perf 10Y | -36.39% |
| Dividend Ex-Date | - | Quick Ratio | 2.92 | EPS Q/Q | -132.66% | Profit Margin | -6.35% | RSI (14) | 51.24 | Recom | 1.6 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.9 | Sales Q/Q | 6.51% | SMA20 | 1.08% ($12.08) | Beta | 1.86 | Target Price | $14 |
| Payout | - | Debt/Eq | 0.37 | Earnings | 2026/10/6 | SMA50 | 0.08% ($12.2) | Rel Volume | 0.51 | Prev Close | $12.19 |
| Employees | 2636 | LT Debt/Eq | 0.37 | EPS/Sales Surpr. | 50.09% 7.03% | SMA200 | 17.82% ($10.36) | Avg Volume(3M) | 3.32M | Price | $12.21 |
| IPO | 1989/8/23 | Option/Short | Yes/Yes | Trades | 14155 | Volume | 1,691,957 | Change | 0.16% |
🔬 This U.S.-based company provides diagnostic and testing solutions for food and animal safety. It supplies pathogen and contaminant testing for food, animal health and genomic diagnostics, and biosecurity products, with reusable test kits and consumables serving as its core offerings. The company has established itself as a specialized diagnostics and testing provider supporting safety across the food, agriculture, and animal industries.
Over the past 1 year, on the higher side
14% below its 1-year high.
Traded less than usual. That is 51% of its average volume.
NEOG keeps an operating profit but posts a net loss
Of every $100 in sales, $0.01 is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +4.2% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $302. Peers typically go for $248. Compared with its own 2-year average, it is 1197% pricier now.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 5 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -71.0%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 109.8%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #23 of 141 in the industry
Based on market cap of $3B.
FAQ
What kind of company is NEOG?
NEOG belongs to the Healthcare sector and operates in the Medical Devices industry.
What is the market cap of NEOG?
The market cap of NEOG is approximately $2.7B, ranking 1,822 within its sector.
What is the 52-week high and low for NEOG?
NEOG has recorded a 52-week high of $14.26 and a low of $5.37.
